申请人:NIPPON ZOKI PHARMACEUTICAL CO., LTD.
公开号:EP0967220A1
公开(公告)日:1999-12-29
[Objects]
An object of the present invention is to offer an Ara-A derivative having a resistance to the metabolism by ADA and also having a sufficient antiviral action.
[Constitution]
A novel 2-substituted arabinosyladenine derivative represented by the formula (I) and pharmaceutically acceptable salts and hydrates thereof.
[In the formula, Z is alkyl having more than 4 carbon atoms, alkenyl or alkynyl and R is hydrogen or lower alkyl.]
[Merit]
The compounds of the present invention are Ara-A derivatives having a resistance to the metabolism by ADA and having a sufficient antiviral action whereby the problems in the prior art have been solved. The compounds of the present invention are useful as therapeutic or preventive agents for diseases infected by DNA virus such as herpes simplex virus (HSV), herpes zoster virus, cytomegalovirus (CMV), adenovirus, hepatitis virus or vaccinia virus. As compared with Ara-A, they not only show a good behavior in blood with an excellent sustaining property but also are capable of being orally administered whereby their usefulness is very high.
目的
本发明的目的是提供一种 Ara-A 衍生物,该衍生物具有抗 ADA 代谢的能力,并具有足够的抗病毒作用。
构成
一种由式(I)代表的新型 2-取代的阿拉伯核糖基腺嘌呤衍生物及其药学上可接受的盐和水合物。
[式中,Z 为具有 4 个以上碳原子的烷基、烯基或炔基,R 为氢或低级烷基。]
优点
本发明的化合物是 Ara-A 衍生物,具有抗 ADA 代谢的能力和足够的抗病毒作用,从而解决了现有技术中存在的问题。本发明的化合物可作为治疗或预防 DNA 病毒感染疾病的药物,如单纯疱疹病毒(HSV)、带状疱疹病毒、巨细胞病毒(CMV)、腺病毒、肝炎病毒或疫苗病毒。与 Ara-A 相比,它们不仅在血液中表现良好,具有出色的持续性,而且能够口服给药,因此具有很高的实用性。